Mirikizumab

Drug Profile

Mirikizumab

Alternative Names: Anti-IL-23 MAb; Anti-IL-23 monoclonal antibody; Anti-interleukin-23 MAb; Anti-interleukin-23 monoclonal antibody; LY-3074828

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Inflammation mediator inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Plaque psoriasis; Ulcerative colitis

Most Recent Events

  • 21 Jun 2017 Eli Lilly plans a phase I trial in Healthy volunteers in USA (NCT03188510)
  • 10 May 2017 LY3074828 is now called Mirikizumab (NCT03053622)
  • 24 Apr 2017 Eli Lilly initiates a phase I trial in Healthy volunteers in United Kingdom (IV and SC) (NCT03053622)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top